NLSP - Income Statement - NLS Pharmaceutics AG

	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017
REVENUE
Revenue	0	0	0	0	0	0	0
GROSS PROFIT
Cost Of Revenue	11.4 K	11.4 K	10 K	0	0	0	0
Gross Profit	11.4 K	11.4 K	10 K	0	0	0	0
OPERATING INCOME
Operating Expenses	11.8	15.5	11.9	2.3	4.2	3.45 K	5.8
Selling, General and Administrative Expenses	5.9	6.5	5.9	2.2	2.5	2.74 K	1.4
Research and Development Expenses	5.9	9.0	5.9	99.6 K	1.7	708	4.3
Operating Income	(11.8)	(15.5)	(11.9)	(2.3)	(4.2)	3.45 K	(5.8)
PRE-TAX INCOME
Interest Income Expense	0.1	0.1	68.1 K	0.2	0.8	0	0.9
Total Other Income	(0.4)	(1.0)	85.5 K	(0.6)	(1.3)	1.7 K	(0.9)
Pre-Tax Income	(12.2)	(16.5)	(11.9)	(2.9)	(5.4)	5.15 K	(6.7)
NET INCOME
Tax Provision	0	2	(0.2)	2.3 K	4.2 K	0	5.77 K
Net Income	(12.2)	(16.5)	(11.9)	(2.9)	(5.4)	5.15 K	(6.7)
EPS	0.32	0.84	0.81	0.59	0.49	33	0.57

Free